Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Intermountain Health Platte Valley Hospital — Brighton, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers - Boulder — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Colorado: - University of Colorado Hospital-Anschutz Cancer Pavilion — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Colorado: - University of Colorado — Aurora, Colorado
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Colorado: - Central Recruiting Site — Wheat Ridge, Colorado
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 2 Recruiting Academic/Other
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main g…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT07011576
Sites in Colorado: - Rocky Mountain Cancer Center - Primary — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received t…
Sponsor: GlaxoSmithKline
NCT ID: NCT06885034
Sites in Colorado: - GSK Investigational Site — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Colorado: - Sarah Cannon Research Institute at HealthOne — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 2 Recruiting Industry
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable …
Sponsor: Kahr Bio Australia Pty Ltd
NCT ID: NCT07235293
Sites in Colorado: - University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP) — Aurora, Colorado
- University of Colorado Cancer Center - Highlands Ranch Hospital — Highlands Ranch, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of thi…
Sponsor: BioNTech SE
NCT ID: NCT07186842
Sites in Colorado: - SCRI at HCA Health One — Denver, Colorado
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 1 Recruiting Industry
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
Phase 1 Recruiting Industry
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT03715933
Sites in Colorado: - University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor typ…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07503808
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1 Recruiting Industry
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Sponsor: Incyte Corporation
NCT ID: NCT06179160
Sites in Colorado: - Sarah Cannon Research Institue At Healthone — Denver, Colorado
Phase 1 Recruiting Industry
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participan…
Sponsor: Genentech, Inc.
NCT ID: NCT05581004
Sites in Colorado: - University Of Colorado — Aurora, Colorado
Phase 1 Recruiting Industry
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itsel…
Sponsor: Kumquat Biosciences Inc.
NCT ID: NCT06720987
Sites in Colorado: - Sarah Cannon Cancer Institute at HealthONE — Denver, Colorado
Phase 1 Recruiting Industry
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07066657
Sites in Colorado: - University of Colorado — Aurora, Colorado
- Sarah Cannon Research Institute — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recur…
Sponsor: Context Therapeutics Inc.
NCT ID: NCT06756035
Sites in Colorado: - Context Investigational Site — Denver, Colorado